Deepu Madduri: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Deepu Madduri, MD, discusses data from the phase Ib/II CARTITUDE-1 study evaluating chimeric antigen receptor (CAR) T cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.